


(\pm) 11(12)-EET

Chemical Properties

CAS No. :	123931-40-8
Formula:	C ₂₀ H ₃₂ O ₃
Molecular Weight:	320.47
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	(\pm) 11(12)-EET is a fully racemic version of the R/S enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes.[1][2][3] A higher proportion of 11(R),12(S)-EET is produced by the CYP450 isoforms CYP2C23 and CYP2C24, while CYP2B2 produces a higher proportion of 11(S),12(R)-EET.[3] 11(12)-EET has been shown, along with 8(9)-EET, to play a role in the recovery of depleted calcium pools in cultured smooth muscle cells.[4] It also inhibits basolateral 18-pS potassium channels in the renal cortical collecting duct at a concentration of 100 nM.[5] 11(12)-EET (50 µg/kg per day) increases adhesion of isolated peripheral blood leukocytes in a chamber coated with P-selectin and ICAM-1 but does not affect choroidal neovascularization size following laser photocoagulation.[6] It also has anti-inflammatory, angiogenic, and cardioprotective properties.[7]
Targets(IC50)	Others,NOD-like Receptor (NLR)

Solubility Information

Solubility	PBS (pH 7.2): >1 mg/mL (from 13(S)-HODE),Sonication is recommended. Ethanol: >50 mg/mL (per Rao Maddipati),Sonication is recommended. DMF: >50 mg/mL (per Rao Maddipati),Sonication is recommended. DMSO: >50 mg/mL (per Rao Maddipati),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.1204 mL	15.6021 mL	31.2042 mL
5 mM	0.6241 mL	3.1204 mL	6.2408 mL
10 mM	0.312 mL	1.5602 mL	3.1204 mL
50 mM	0.0624 mL	0.312 mL	0.6241 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Chacos, N., Falck, J.R., Wixtrom, C., et al. Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acid. *Biochem. Biophys. Res. Commun.* 104(3), 916-922 (1982).
- Oliw, E.H., Guengerich, F.P., and Oates, J.A. Oxygenation of arachidonic acid by hepatic monooxygenases. Isolation and metabolism of four epoxide intermediates. *J. Biol. Chem.* 257(7), 3771-3781 (1982).
- Capdevila, J.H., Falck, J.R., and Harris, R.C. Cytochrome P450 and arachidonic acid bioactivation: Molecular and functional properties of the arachidonate monooxygenase. *J. Lipid Res.* 41(2), 163-181 (2000).
- Graber, M.N., Alfonso, A., and Gill, D.L. Recovery of Ca²⁺ pools and growth in Ca²⁺ pool-depleted cells is mediated by specific epoxyeicosatrienoic acids derived from arachidonic acid. *J. Biol. Chem.* 272(47), 29546-29553 (1997).
- Wang, Z., Wei, Y., Falck, J.R., et al. Arachidonic acid inhibits basolateral K channels in the cortical collecting duct via cytochrome P-450 epoxygenase-dependent metabolic pathways. *Am. J. Physiol. Renal Physiol.* 294(6), F1441-F1447 (2008).
- Hasegawa, E., Inafuku, S., Mulki, L., et al. Cytochrome P450 monooxygenase lipid metabolites are significant second messengers in the resolution of choroidal neovascularization. *Proc. Natl. Acad. Sci. U.S.A.* 114(36), E7545-E7553 (2017).
- Spector, A.A. Arachidonic acid cytochrome P450 epoxygenase pathway. *J. Lipid Res.* 50(Suppl), S52-S56 (2009).

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481